QuidelOrtho - QDEL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $66.50
  • Forecasted Upside: 44.10%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$46.15
▼ -0.65 (-1.39%)

This chart shows the closing price for QDEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New QuidelOrtho Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QDEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QDEL

Analyst Price Target is $66.50
▲ +44.10% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for QuidelOrtho in the last 3 months. The average price target is $66.50, with a high forecast of $81.00 and a low forecast of $37.00. The average price target represents a 44.10% upside from the last price of $46.15.

This chart shows the closing price for QDEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in QuidelOrtho. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2024Craig HallumReiterated RatingBuy ➝ HoldLow
2/14/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$130.00 ➝ $81.00Low
2/14/2024William BlairReiterated RatingOutperform ➝ Market PerformLow
2/14/2024Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$100.00 ➝ $76.00Low
2/14/2024JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$66.00 ➝ $37.00Low
12/21/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$140.00 ➝ $130.00Low
12/11/2023CitigroupReiterated RatingBuy ➝ Neutral$95.00 ➝ $72.00Low
11/2/2023Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$110.00 ➝ $100.00N/A
11/2/2023William BlairReiterated RatingOutperformLow
9/19/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$140.00Low
8/15/2023Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$130.00 ➝ $110.00Low
8/9/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$136.00Low
8/9/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$91.00 ➝ $85.00N/A
2/16/2023Raymond JamesLower TargetStrong-Buy$136.00 ➝ $130.00Low
2/16/2023Royal Bank of CanadaBoost TargetOutperform$125.00 ➝ $136.00Low
12/14/2022Craig HallumLower Target$173.00Low
12/12/2022CitigroupUpgradeNeutral ➝ Buy$90.00 ➝ $125.00Low
12/6/2022Royal Bank of CanadaInitiated CoverageOutperform$125.00Low
11/3/2022JPMorgan Chase & Co.Lower TargetNeutral$100.00 ➝ $93.00Low
10/14/2022UBS GroupUpgradeSell ➝ Neutral$86.00Low
9/19/2022CitigroupInitiated CoverageNeutral$90.00Low
7/20/2022UBS GroupInitiated CoverageSell$86.00Low
6/17/2022JPMorgan Chase & Co.Initiated CoverageUnderweight ➝ NeutralHigh
2/22/2022Raymond JamesUpgradeOutperform ➝ Strong-Buy$155.00 ➝ $130.00High
10/8/2021JPMorgan Chase & Co.Boost TargetOverweight$70.00 ➝ $80.00Medium
8/6/2021Raymond JamesBoost TargetOutperform$141.00 ➝ $155.00Low
6/28/2021Raymond JamesLower TargetOutperform$160.00 ➝ $141.00High
6/17/2021Craig HallumLower TargetBuy$296.00 ➝ $219.00Low
6/4/2021JPMorgan Chase & Co.Lower TargetUnderweight$90.00 ➝ $80.00High
5/7/2021Raymond JamesLower TargetOutperform$180.00 ➝ $160.00High
5/7/2021JPMorgan Chase & Co.Lower TargetUnderweight$95.00 ➝ $90.00High
4/23/2021JPMorgan Chase & Co.Lower Target$120.00 ➝ $95.00High
4/23/2021Piper SandlerLower Target$265.00 ➝ $140.00High
3/17/2021Raymond JamesLower TargetOutperform$245.00 ➝ $180.00N/A
3/11/2021Craig HallumLower TargetBuy$371.00 ➝ $341.00Low
3/11/2021Raymond JamesLower TargetOutperform$245.00 ➝ $180.00Low
2/25/2021Raymond JamesLower TargetOutperform$250.00 ➝ $245.00Medium
2/19/2021JPMorgan Chase & Co.Lower TargetUnderweight$175.00 ➝ $170.00High
1/22/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$250.00High
10/30/2020JPMorgan Chase & Co.Boost TargetUnderweight$185.00 ➝ $190.00Medium
7/31/2020Craig HallumBoost TargetPositive ➝ Buy$306.00 ➝ $363.00Medium
7/31/2020Piper SandlerBoost TargetOverweight$250.00 ➝ $360.00High
7/8/2020Piper SandlerBoost TargetOverweight$168.00 ➝ $250.00Medium
7/7/2020Craig HallumBoost TargetBuy$170.00 ➝ $306.00Medium
5/12/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$120.00 ➝ $158.00High
5/7/2020Craig HallumBoost TargetMarket Perform ➝ Buy$125.00 ➝ $170.00Medium
3/26/2020BarclaysReiterated RatingOverweight ➝ Equal Weight$90.00High
3/19/2020Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
2/13/2020Raymond JamesBoost TargetStrong-Buy$70.00 ➝ $92.00Medium
8/29/2019Craig HallumUpgradeHold ➝ Buy$63.00 ➝ $75.00High
4/15/2019Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$72.00 ➝ $74.00Medium
3/18/2019BarclaysBoost TargetOverweight ➝ Overweight$74.00 ➝ $77.00High
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/2/2023
  • 10 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/1/2023
  • 12 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/1/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/31/2023
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2023
  • 7 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/30/2023
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 10 very positive mentions
  • 41 positive mentions
  • 9 negative mentions
  • 1 very negative mentions
2/28/2024

Current Sentiment

  • 10 very positive mentions
  • 41 positive mentions
  • 9 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

QuidelOrtho logo
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $46.15
Low: $45.77
High: $46.32

50 Day Range

MA: $66.28
Low: $41.76
High: $75.44

52 Week Range

Now: $46.15
Low: $41.75
High: $98.67

Volume

143,536 shs

Average Volume

1,076,443 shs

Market Capitalization

$3.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of QuidelOrtho?

The following sell-side analysts have issued reports on QuidelOrtho in the last twelve months: Citigroup Inc., Craig Hallum, JPMorgan Chase & Co., Raymond James, Royal Bank of Canada, StockNews.com, and William Blair.
View the latest analyst ratings for QDEL.

What is the current price target for QuidelOrtho?

4 Wall Street analysts have set twelve-month price targets for QuidelOrtho in the last year. Their average twelve-month price target is $66.50, suggesting a possible upside of 44.1%. Royal Bank of Canada has the highest price target set, predicting QDEL will reach $81.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $37.00 for QuidelOrtho in the next year.
View the latest price targets for QDEL.

What is the current consensus analyst rating for QuidelOrtho?

QuidelOrtho currently has 1 sell rating, 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in QDEL, but not buy more shares or sell existing shares.
View the latest ratings for QDEL.

What other companies compete with QuidelOrtho?

How do I contact QuidelOrtho's investor relations team?

QuidelOrtho's physical mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company's listed phone number is (800) 874-1517 and its investor relations email address is [email protected]. The official website for QuidelOrtho is www.quidel.com. Learn More about contacing QuidelOrtho investor relations.